Risk of Thromboembolism With Eltrombopag: A Case Report of Deep Vein Thrombosis and Bilateral Pulmonary Embolism

Eltrombopag is a second-line therapy for refractory thrombocytopenia from immune thrombocytopenic purpura (ITP). The medication is generally well tolerated but can lead to adverse thromboembolic complications in rare instances. We present a case of lower extremity deep vein thrombosis with bilateral...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2023-01, Vol.15 (1), p.e33615
Main Authors: Ghumman, Ghulam Mujtaba, Fatima, Huda, Singh, Gunbir, Khalid, Taha, Ayoubi, Mohamed
Format: Article
Language:English
Subjects:
Anticoagulants
Case reports
Hematology
Immunoglobulins
Immunosuppressive agents
Internal Medicine
Patients
Pulmonary embolisms
Purpura
Thrombocytopenia
Thromboembolism
Thrombosis
Veins & arteries
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eltrombopag is a second-line therapy for refractory thrombocytopenia from immune thrombocytopenic purpura (ITP). The medication is generally well tolerated but can lead to adverse thromboembolic complications in rare instances. We present a case of lower extremity deep vein thrombosis with bilateral pulmonary embolism in an ITP patient receiving eltrombopag. The patient underwent catheter-directed thrombolysis for pulmonary embolism. Eltrombopag was stopped on discharge, considering the potential cause of venous thrombosis.
ISSN:2168-8184
2168-8184
DOI:10.7759/cureus.33615